These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9407708)

  • 21. Cell specific quantitative iron mapping on brain slices by immuno-µPIXE in healthy elderly and Parkinson's disease.
    Friedrich I; Reimann K; Jankuhn S; Kirilina E; Stieler J; Sonntag M; Meijer J; Weiskopf N; Reinert T; Arendt T; Morawski M
    Acta Neuropathol Commun; 2021 Mar; 9(1):47. PubMed ID: 33752749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
    Dexter DT; Wells FR; Lees AJ; Agid F; Agid Y; Jenner P; Marsden CD
    J Neurochem; 1989 Jun; 52(6):1830-6. PubMed ID: 2723638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.
    Ben-Shachar D; Youdim MB
    J Neural Transm Suppl; 1990; 29():251-8. PubMed ID: 2193109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
    Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
    BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mechanism of α-lipoic acid promoting iron efflux in substantia nigra cells of Parkinson's disease rats].
    Cai T; Wei C; Zhai S; Tai S; Zhang C; Jiao L
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2018 Jan; 34(1):35-40. PubMed ID: 29595455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigations of differences in iron oxidation state inside single neurons from substantia nigra of Parkinson's disease and control patients using the micro-XANES technique.
    Chwiej J; Adamek D; Szczerbowska-Boruchowska M; Krygowska-Wajs A; Wojcik S; Falkenberg G; Manka A; Lankosz M
    J Biol Inorg Chem; 2007 Feb; 12(2):204-11. PubMed ID: 17120075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteopontin expression in substantia nigra in MPTP-treated primates and in Parkinson's disease.
    Iczkiewicz J; Jackson MJ; Smith LA; Rose S; Jenner P
    Brain Res; 2006 Nov; 1118(1):239-50. PubMed ID: 16962083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
    Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
    J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Iron accumulation in the substantia nigra in rats visualized by ultrasound.
    Berg D; Grote C; Rausch WD; Mäurer M; Wesemann W; Riederer P; Becker G
    Ultrasound Med Biol; 1999 Jul; 25(6):901-4. PubMed ID: 10461717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammation and age-related iron accumulation in F344 rats.
    Hunter RL; Liu M; Choi DY; Cass WA; Bing G
    Curr Aging Sci; 2008 Jul; 1(2):112-21. PubMed ID: 20021380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker.
    Berg D; Hochstrasser H; Schweitzer KJ; Riess O
    Neurotox Res; 2006 Jan; 9(1):1-13. PubMed ID: 16464747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear accumulation of GAPDH, GluA2 and p53 in post-mortem substantia nigral region of patients with Parkinson's disease.
    Sekar S; Taghibiglou C
    Neurosci Lett; 2020 Jan; 716():134641. PubMed ID: 31759082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Magnetic resonance imaging assessment of substantia nigral iron deposition in Parkinson's disease: a meta-analysis.
    Liu GL; Zhang HW; Zha CB; Fan TW; Chen ST; Shen TT; He K
    Eur Rev Med Pharmacol Sci; 2024 Feb; 28(3):899-906. PubMed ID: 38375696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oxidative stress and Parkinson's disease.
    Owen AD; Schapira AH; Jenner P; Marsden CD
    Ann N Y Acad Sci; 1996 Jun; 786():217-23. PubMed ID: 8687021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of transition metals in the pathogenesis of Parkinson's disease.
    Kienzl E; Puchinger L; Jellinger K; Linert W; Stachelberger H; Jameson RF
    J Neurol Sci; 1995 Dec; 134 Suppl():69-78. PubMed ID: 8847547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping.
    He N; Ling H; Ding B; Huang J; Zhang Y; Zhang Z; Liu C; Chen K; Yan F
    Hum Brain Mapp; 2015 Nov; 36(11):4407-20. PubMed ID: 26249218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?
    Kaur D; Andersen JK
    Aging Cell; 2002 Oct; 1(1):17-21. PubMed ID: 12882349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of freezing of gait with nigral iron accumulation in patients with Parkinson's disease.
    Naduthota RM; Honnedevasthana AA; Lenka A; Saini J; Geethanath S; Bharath RD; Christopher R; Yadav R; Gupta AK; Pal PK
    J Neurol Sci; 2017 Nov; 382():61-65. PubMed ID: 29111022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.